SEC Tracker
Get the app

ArriVent BioPharma AVBP

ArriVent BioPharma doses first patient in Phase 1 trial

Form
8-K
Filed
Importance
Routine
  1. October 12, 2026 - First patient dosed with ARR-002
  2. ARR-002 is a dual-target tetravalent ADC for ovarian and endometrial cancer
  3. Phase 1 trial (NCT07755436) evaluates safety and efficacy
  4. Exclusive licensing agreement with Shanghai Allist for Greater China

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when ArriVent BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. uniQure QURE public float $765M, Jun 30, 2025
  3. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  4. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  5. Immunome IMNM public float $729M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.